NCT07419581 A Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment
| NCT ID | NCT07419581 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Case Comprehensive Cancer Center |
| Condition | Dysgeusia |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2026-09 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2026-09 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is for people with a diagnosis of solid tumor cancer who are experiencing changes in taste perception due to cancer treatment. Changes in taste perception, also known as dysgeusia, is a frequent side effect of cancer treatment and can significantly impacts quality of life. These alterations may be temporary or, in some cases, permanent. The purpose of this study is determine whether freeze dried miracle fruit, marketed as MiraBurst can improve taste perception in this group of people. Participants involved in this study will be asked to take one MiraBurst mini-square upto four times a day, prior to eating, for 90 days.
Eligibility Criteria
Inclusion Criteria: * Age 18 years and above * Solid tumor cancer diagnosis * Participants on active cancer treatment * Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 * Grade 2 dysgeusia related to cancer treatment per Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 Exclusion Criteria: * Grade 2 dysgeusia prior to starting cancer treatment * Participants with severe dementia, severe neurological illness who are unable to understand the study or provide informed consent * Participants on enteral and parenteral nutrition * Participants with eating disorders * Pregnancy * Participants with uncontrolled acute medical issues (e.g., acute angina, acute stroke, uncontrolled diabetes mellitus, uncontrolled hypertension etc.) that, per investigator's assessment, would contraindicate the study treatment
Contact & Investigator
Shirley Thomas, MD, MRCP (UK), MRCP (UK) Pall Med, PGDip Pall Med
✉ thomass75@ccf.org📞 216-445-0132
Shirley Thomas, MD, MRCP (UK), MRCP (UK) Pall Med, PGDip Pall Med
PRINCIPAL INVESTIGATOR
Case Comprehensive Cancer Center, Cleveland Clinic
Frequently Asked Questions
Who can join the NCT07419581 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dysgeusia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07419581 currently recruiting?
Yes, NCT07419581 is actively recruiting participants. Contact the research team at thomass75@ccf.org for enrollment information.
Where is the NCT07419581 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT07419581 clinical trial?
NCT07419581 is sponsored by Case Comprehensive Cancer Center. The principal investigator is Shirley Thomas, MD, MRCP (UK), MRCP (UK) Pall Med, PGDip Pall Med at Case Comprehensive Cancer Center, Cleveland Clinic. The trial plans to enroll 45 participants.